Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 69

Results For "subsidiary"

872 News Found

USFDA removes Jubilant Generics' Olanzapine, Spironolactone and Valsartan from the excepted products list
Drug Approval | July 14, 2022

USFDA removes Jubilant Generics' Olanzapine, Spironolactone and Valsartan from the excepted products list

Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.


WuXi STA opens Oligonucleotide and Peptide manufacturing facility
News | July 08, 2022

WuXi STA opens Oligonucleotide and Peptide manufacturing facility

Site Enhances New Modality CRDMO Platform Capacity for Customers


Eugia Pharma receives USFDA approval for Triamcinolone Acetonide Injectable Suspension
Drug Approval | July 07, 2022

Eugia Pharma receives USFDA approval for Triamcinolone Acetonide Injectable Suspension

This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.


Biocon Biologics receives EU GMP Certification for its in Bengaluru
News | July 06, 2022

Biocon Biologics receives EU GMP Certification for its in Bengaluru

This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.


Jubilant HollisterStier announces CAD 100 mn for Montreal facility
News | July 01, 2022

Jubilant HollisterStier announces CAD 100 mn for Montreal facility

The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million


India’s first mRNA vaccine from Gennova gets DCGI approval
Drug Approval | June 30, 2022

India’s first mRNA vaccine from Gennova gets DCGI approval

It is a two dose vaccine to be administered intramuscularly at 28 days apart


Glenmark Pharmaceuticals expand its OTC portfolio
News | June 29, 2022

Glenmark Pharmaceuticals expand its OTC portfolio

The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world


Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D
People | June 24, 2022

Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D

Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.


Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Drug Approval | June 23, 2022

Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients